Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Geref · GRF(1–29)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GHRH peptide analogue
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Stimulates pituitary GH secretion.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Handbooks describe GH support and nighttime regimens. The guide distinguishes diagnosed deficiency, historical diagnostic use and wellness use rather than treating them as one indication.
Human evidence
Historical diagnostic/pediatric development does not validate adult anti-aging use.
Preclinical evidence
Physiological GH release is not proof of rejuvenation.
Critical reading and limitations
The official document reviewed found that the discontinued product was not withdrawn for safety or effectiveness reasons. That conclusion does not prove anti-aging efficacy, replace trials of current formulations or establish equivalence of combinations.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
200–300 mcg · Amount per administration
- Frequency
- Once daily, before bed per source.
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Described GH support.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 138 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US: Geref discontinued; FDA determined it was not withdrawn for safety/effectiveness reasons. This is not approval of current compounded products.
Adverse effects and unknowns
Current compounded-product safety and interactions cannot be inferred from the discontinued branded product.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Sermorelin · 27 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06554717 · Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVRegistry status: RecruitingLast update posted: May 19, 2026Query verification: October 16, 2026
NCT03375788 · Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskRegistry status: CompletedLast update posted: November 20, 2025Query verification: October 16, 2026
NCT00720902 · Adult Growth Hormone Deficiency and Cardiovascular RiskRegistry status: TerminatedLast update posted: November 16, 2022Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-SERM
Geref: withdrawal not for safety/effectiveness
October 16, 2026
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026